In the current study, we report the effects of both siRNA and novel small-molecule inhibitors of MAP3K19 in primary human IPF fibroblasts and a SCID mouse model of IPF induced by the intravenous injection of IPF fibroblasts9,10. Here, MAP3K19 is linked to idiopathic pulmonary fibrosis.